Diabetic Kidney Disease

Highlights Hub

Expert Highlights & Perspectives

Watch as experts George L. Bakris, MD, Rajiv Agarwal, MD, and Janet McGill, MD, discuss additional clinical pearls on DKD progression and the emerging role of novel non-steroidal MRAs for the treatment of DKD

Janet McGill, MD
Janet McGill,
MD
George L, Bakris, MD
George L, Bakris,
MD

INTERVIEW #1

EVALUATING THE RISK FOR DKD PROGRESSION

Watch the experts share some highlights including:

  • Early recognition and screening for DKD
  • Monitoring kidney function
  • Risk factors for DKD progression
Play
Rajiv Agarwal, MD
Rajiv Agarwal,
MD
George L, Bakris, MD
George L, Bakris,
MD

INTERVIEW #2

THE RATIONALE FOR NON-STEROIDAL MRAS IN DKD

Watch the experts share some highlights including:

  • Differentiating between steroidal and non-steroidal MRAs
  • Adverse events and limitations with steroidal MRAs in DKD
  • Advantages of finerenone in DKD
  • The overview of kidney results of the FIDELIO trial
Play
Rajiv Agarwal, MD
Rajiv Agarwal,
MD
George L, Bakris, MD
George L, Bakris,
MD

INTERVIEW #3

THE CARDIOVASCULAR BENEFITS OF FINERENONE

Watch the experts share some highlights including:

  • The interplay between the kidney and heart
  • CVD benefits of finerenone: analysis from the FIDELIO trial and ongoing CVD studies with finere none
  • How does finerenone fit within the context of SGLT-2is
Play
George L, Bakris, MD
George L, Bakris,
MD

INTERVIEW #4

FINERENONE: PUTTING THE DATA INTO CONTEXT

Watch the experts share some highlights including:

  • Finerenone in the context of existing treatments
  • Clinical pearls for incorporating finerenone to the DKD treatment armamentarium in the near future
Play